netFormulary NHS
Lancashire and South Cumbria
Formulary
 Search
 Results

Looking for Dapagliflozin found 12 matches
Open monograph to display formulary status BNF Category
  Dapagliflozin  (Forxiga®) Cardiovascular system - Heart Failure - 02.05.05
  Dapagliflozin  (Forxiga®) Endocrine system - SGLT2 inhibitors - 06.01.02.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update December 2021: Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus (06.01.02.03)
link in drug section MHRA Drug Safety update June 2015: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis (06.01.02.03)
link in drug section NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes (06.01.02.03)
link in drug section NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (06.01.02.03)
link in drug section NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (06.01.02.03)
link in drug section NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (06.01.02.03)
link in drug section NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes (06.01.02.03)
link in drug section NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction (02.05.05)
link in drug section NICE TA775: Dapagliflozin for treating chronic kidney disease (06.01.02.03)
link in drug section NICE TA902: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (02.05.05)


 
netFormulary